Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar, adalimumab) in Australia and Canada

March 30, 2021 Auto Bot Australia, Biosimilar, Biosimilars, Canada, Expand, Samsung Bioepis 0

Shots:

  • Samsung Bioepis in collaboration with Merck broadens its global reach by launching Hadlima in Australia for multiple autoimmune diseases
  • With the launch in Australia, Samsung Bioepis’ adalimumab is now available in three markets: Europe, Canada, and Australia
  • Hadlima is Samsung Bioepis’ third anti-TNF biosimilar launched in Australia, following the launch of Brenzys (etanercept) and Renflexis (infliximab). Hadlima will be available on the PBS from Apr 01, 2021

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: BusinessWire

The post Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar, adalimumab) in Australia and Canada first appeared on PharmaShots.